Skip to main content
. 2023 Jul 27;23:277. doi: 10.1186/s12890-023-02578-2

Table 2.

Etiological detection tests of patients with cryptococcosis

Test items Pulmonary cryptococcosis Extrapulmonary cryptococcosis
Surgical Nonsurgicalb Intracranial cryptococcosis Cryptococcemia
Serum LFA 40% (2/5) 86.7% (13/15) 100% (6/6) 100% (1/1)
CSF LFA -- 0% (0/5) 100% (5/5) --
Serum LA 100% (1/1) 100% (6/6) -- 100% (1/1)
CSF LA -- -- 100% (2/2) --
Serum GXM 100% (1/1) 100% (7/7) 100% (2/2) --
CSF culture 0% (0/1) 0% (0/2) 45.5% (5/11) --
India ink test 0% (0/2) 0% (0/5) 54.5% (6/11) --
Pathology 100% (32/32) 100% (23/23) 100% (1/1) --
Blood culture -- -- 0 (0/10) 100% (5/5)a
Bone marrow culture -- -- 0 (0/1) 100% (1/1)a

All the tests were conducted before antifungal therapy or surgical resection. All the data were presented as percentage (positive population/ total detected population). Among 11 patients with intracranial cryptococcosis, 5 didn’t have chest CT scan. None of EPC patients underwent pulmonary pathological and microbiological examinations to diagnose PC. Some subjects in PC/EPC group were positive for more than one tests. Detailed data can be obtained from the first author

--: Nobody in the cohort had specified test results

GXM: capsular polysaccharide glucuronoxylomannan

aOne patient has both blood culture and bone marrow culture positive for Cryptococcus

bNonsurgical PC patients were generally treated in respiratory ward and diagnosed via percutaneous lung biopsy